Does adding exercise or physical activity to pharmacological osteoporosis therapy in patients with increased fracture risk improve bone mineral density and lower …

AK Schumm, EA Craige, NK Arora, PJ Owen… - Osteoporosis …, 2023 - Springer
This prospectively registered systematic review and meta-analysis examines whether
exercise (EX) training has an additive effect to osteoanabolic and/or antiresorptive …

Mechanistic advances in osteoporosis and anti‐osteoporosis therapies

H Wang, Y Luo, H Wang, F Li, F Yu, L Ye - MedComm, 2023 - Wiley Online Library
Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and
microarchitectural deterioration of bone tissue. With the intensification of global aging, this …

Teriparatide in postmenopausal osteoporosis: uncovering novel insights into efficacy and safety compared to other treatments–a systematic review and meta-analysis

DTA Vithran, AE Essien, M Rahmati… - EFORT Open …, 2024 - eor.bioscientifica.com
Objective The aim of the study was to evaluate the efficacy and safety of teriparatide
compared to other treatments for postmenopausal osteoporosis. Methods A review of …

Latest on anabolic agents for osteoporosis treatment

L di Filippo, CJ Rosen - Endocrinology and Metabolism Clinics, 2024 - endo.theclinics.com
Osteoporosis is a systemic skeletal disorder characterized by progressive deterioration in
bone quantity and quality leading to increased risk of fragility fractures. 1, 2 Skeletal tissue is …

Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle

J Gostage, P Kostenuik, K Goljanek-Whysall… - Current osteoporosis …, 2024 - Springer
Abstract Purpose of Review This review aims to consolidate recent observations regarding
extra-osseous roles of the RANK-RANKL-OPG axis, primarily within skeletal muscle. Recent …

What's new in osteoporosis and fragility fractures

DG Hansen, T Tutaworn, JM Lane - JBJS, 2022 - journals.lww.com
In this article, we establish a baseline status of clinical and basic research in the area of
osteoporosis and fragility fractures, focused primarily on research published within the past …

[HTML][HTML] Micheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption

Z Gan, J Huang, M Xu, X Yuan, X Shang… - Aging (Albany …, 2023 - ncbi.nlm.nih.gov
Osteoporosis is one of the major health problems characterized by decreased bone density
and increased risk of fractures. Nowadays, the treating strategies against osteoporosis are …

Effects of stepwise administration of osteoprotegerin and parathyroid hormone-related peptide DNA vectors on bone formation in ovariectomized rat model

YJ Eom, JW Kim, YA Rim, J Lim, SI Jung, JH Ju - Scientific Reports, 2024 - nature.com
Osteoporosis is a metabolic bone disease that impairs bone mineral density,
microarchitecture, and strength. It requires continuous management, and further research …

2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

MB Humphrey, L Russell, MI Danila… - Arthritis & …, 2023 - Wiley Online Library
Objective The objective is to update recommendations for prevention and treatment of
glucocorticoid‐induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic …

Intermittent parathyroid hormone enhances the healing of medication-related osteonecrosis of the jaw lesions in rice rats

EJ Castillo, JM Jiron, CS Croft, DG Freehill… - Frontiers in …, 2023 - frontiersin.org
Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
in patients treated with antiresorptives. Management of MRONJ is challenging, and no non …